According to a press release by the Department of Justice, Gilead Sciences, Inc. has infringed upon four U.S. patents in connection with the pharmaceutical company’s Truvada and Descovy, which are marketed to prevent HIV as part of the PrEP regimen.
Support Our Journalism
Click on the reader below to see the latest QNotes Edition.
Chapters in Series
Presented both in English & Spanish
Presentado tanto en inglés como en español
For more articles from the Charlotte Journalism Collaborative, please visit the CJC website.